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Summary  Multidrug-resistant  TB  has  become  a  signiﬁcant  public  health  problem
in  a  number  of  countries  and  an  obstacle  to  effective  TB  control.  Therefore,  the
present  study  sought  to  determine  the  treatment  outcome  in  patients  with  MDR  TB
in  seven  districts  and  to  examine  the  factors  affecting  the  treatment  outcome.  Arate;
Multidrug-resistant
tuberculosis
prospective  cohort  study  was  carried  out  by  enrolling  all  the  registered  patients
in  DOTs  Plus  center  of  Vadodara  district  from  February  2010  to  December  2010.
A  total  of  142  patients  were  interviewed  using  a  pre-tested  semi-structured  ques-
tionnaire  at  the  DOTS  centers  of  seven  districts  of  Gujarat  or  at  their  homes  in
cases  of  defaulters/death.  After  24  months,  of  those  145  patients,  48  (33.10%)  were
declared  cured,  8  (5.50%)  had  completed  their  treatment,  43  (29.70%)  patients  died
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B  is  a  disease  of  major  public  health  impor-
ance. The  global  annual  incidence  estimate  is  9.4
illion cases,  of  which  it  is  estimated  that  2 mil-
ion cases  originate  from  India  [1]. The  emergence
f resistance  to  drugs  used  to  treat  tuberculosis,
peciﬁcally  multidrug-resistant  TB  (MDR-TB),  has
ecome a  signiﬁcant  public  health  problem  in  a
umber of  countries  and  an  obstacle  to  effective  TB
ontrol. India  has  second  highest  MDR-TB  burden  in
he world  after  China  [2].
Relative  to  untreated  TB  patients,  the  probabil-
ty of  treatment  resistance  was  over  4-fold  higher
or previously  treated  patients,  and  that  of  MDR-
B was  over  10-fold  higher  [3]. Multidrug-resistant
uberculosis  (MDR-TB)  is  deﬁned  as  resistance  to
soniazid  and  rifampicin  [4].  Because  these  patients
eed to  be  treated  with  expensive  and  toxic
econd-line drugs  and  may  require  hospitalization
o manage  their  toxic  reactions  and  other  compli-
ations, they  utilize  a  sizeable  proportion  of  health
are resources  [5].
Patient  management,  including  the  duration  of
reatment  and  ﬁnal  treatment  success,  is  based
n the  conversion  of  sputum  smears  to  an  acid-
ast bacilli-negative  status  [6].  For  treatment  of
ultidrug-resistant  TB  or  TB  with  an  isolate  resis-
ant to  at  least  isoniazid  and  rifampicin,  the  status
f mycobacterial  cultures  is generally  used  to  guide
herapy  for  patients  treated  in  resource-limited
ettings and  is  considered  the  most  important
nterim indicator  of  the  efﬁcacy  of  treatment  for
ultidrug-resistant  TB  [7,8].
The  DOTS  Plus  site  in  Vadodara,  the  second  in
he state,  was  established  in  February  2010  for  the
reatment  of  patients  on  MDR-TB  treatment.  The
ismanagement  of  MDR-TB  may  lead  to  the  devel-
pment  of  extensively  drug-resistant  TB  (XDR-TB).
aseline  information  and  adequate  information  on
pidemiological  factors,  treatment  response  dur-
ng the  course  of  treatment,  various  side  effects  of
rugs, and  reasons  for  default  from  previous  treat-
ent are  required  for  disease  control  and  effective
w
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2  (21.10%)  patients  defaulted  during  treatment.  Factors
 difference  in  the  outcomes  were  income,  marital  sta-
ucation  signiﬁcantly  affected  treatment  outcome  upon
Therefore,  proper  counseling  on  drug  adherence  should
tic  level.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
reatment  [9]. Therefore,  the  present  study  was
erformed  to  determine  the  treatment  outcome
n patients  on  MDR  TB  treatment  according  to  the
NTCP regimen  for  MDR-TB  at  seven  districts  of  cen-
ral Gujarat  and  to  examine  the  factors  affecting
he treatment  outcome.
aterial and methods
 prospective  cohort  study  was  carried  out  between
arch 2010  to  January  2013  at  the  DOTS  Plus  site
f Shree  Sayaji  General  Hospital  (SSGH),  Vadodara,
ujarat,  India,  which  receives  an  inﬂow  of  patients
rom seven  districts,  namely  Vadodara  (rural,  urban
nd tribal),  Narmada,  Bharuch,  Panchamahal  and
ahod. All  patients  registered  between  February
010 to  December  2010  at  the  above-mentioned
OTS Plus  sites  were  included  in  the  study  (sample
ize calculation  was  not  required).  Data  collec-
ion was  carried  out  by  obtaining  information
rom treatment  cards  and  by  interviewing  patients.
atients were  conﬁrmed  to  have  MDR-TB  according
o drug  sensitivity  testing  (DST)  results.  Seriously  ill
atients who  were  unable  to  undergo  an  interview,
atients who  refused  to  provide  consent,  patients
nder  the  age  of 18  years,  pregnant  women,  and
atients  with  a concurrent  major  psychiatric  illness
ere excluded  from  the  study.
A total  of 146  patients  from  the  7  aforemen-
ioned districts  were  registered  from  February  to
ecember  2010.  Of  these  146  patients,  one  patient
efused  to  give  consent,  and  3 patients  moved  and
heir treatment  details  were  not  available.  Infor-
ation  about  the  deceased  patients  was  obtained
rom their  relatives;  a  few  of  the  patients  who
ere critically  ill  at the  time  of  interview  were
pproached after  their  health  improved  and  inter-
iews were  obtained.  Therefore,  complete  data
ere available  for  142  patients.  All  the  patients
ere followed  for  24  months  to  determine  the  ﬁnal
utcome.
Pre-treatment  investigations  included  complete
lood count,  renal  and  liver  function  tests,  sputum
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for  acid  fast  bacilli  (AFB),  culture  and  DST,  chest
X-ray,  urine  analysis  for  albumin,  sugar  and  bile
pigment,  pregnancy  test  in  female  patients  of
reproductive  age  and  ELISA  for  HIV  antibodies.
Multidrug-resistant  tuberculosis  (MDR-TB)  was
deﬁned as  resistance  to  isoniazid  and  rifampicin  [4].
Category IV treatment regimen in RNTCP
The  Standardize  Treatment  Regimen  (Cat  IV)  of
RNTCP was  used  for  the  treatment  of  MDR-TB  cases
(and those  with  rifampicin  resistance)  under  the
program.  The  Cat  IV  regimen  comprises  6  drugs  —
kanamycin,  oﬂoxacin  (levoﬂoxacin),  ethionamide,
pyrazinamide, ethambutol  and  cycloserine  — for
6—9 months  of  the  intensive  phase  and  4 drugs
— oﬂoxacin  (levoﬂoxacin),  ethionamide,  ethamb-
utol  and  cycloserine  —  during  for  the  18  months
of the  continuation  Phase.  p-Aminosalicylic  acid  is
included in  the  regimen  as  a  substitute  drug  if  any
bactericidal  drug  (K,  Oﬂ,  Z  and  Eto)  or  2  bacterio-
static (E  and  Cs)  drugs  are  not  tolerated  [10].
Ethical considerations
The  study  was  conducted  after  obtaining  approval
from Institutional  Review  Board,  Medical  College,
Baroda.  All  patients  were  enrolled  in  the  study  after
providing  written  and  informed  consent  in  the  local
language.  Privacy  was  ensured  while  the  patients
were interviewed.  The  District  Tuberculosis  Ofﬁ-
cers (DTO)  of  the  aforementioned  7 districts  were
informed  about  this  study  and  their  cooperation  was
solicited.
All 142  patients  were  interviewed  by  using
pretested semi-structured  questionnaire  at  the
DOTS Centre  of  the  respective  districts  when  they
came to  receive  treatment  (if  they  were  still
undergoing extended  treatment),  or  patients  or
their relatives  were  interviewed  at  their  homes
(in cases  of  defaulters/death).  Each  interview
took approximately  15—20  min  and  the  local  lan-
guage  of  the  area  was  preferred.  The  patients
were asked  questions  related  to  their  treatment
compliance and  various  adverse  drug  reactions
(ADRs) experienced  with  the  present  treatment,
and relevant  ﬁndings  and  responses  were  recorded
during the  interview.  The  enrolled  patients  were
also asked  regarding  their  time  of  acquisition  of
TB, and  their  type  of  default  in  previous  treatment
was noted  on  their  DOTS  Plus  cards.  The  patient
cards at  DOTS  Plus  site  were  used  to  extract  the
required  details:  sputum  culture  reports,  details
of changes  in  treatment  in  patients  with  ADRs,  and
drug compliance.  Six  monthly  treatment  outcomes
on the  basis  of  sputum  and  culture  reports,  the
t
m
t
uS.V.  Patel  et  al.
2-month  treatment  outcome,  the  ﬁnal  outcome
t the  end  of  24  months  (as  per  DOTS  Plus  RNTCP
uidelines), various  ADRs,  and  the  relevant  ﬁndings
f patients  were  also  assessed  based  on  the  records
nd were  veriﬁed  by  personal  interview.  The
atients’ compliance  was  checked  based  on  the
otes in  their  respective  cards.  Data  triangulation
as performed  by  asking  the  DOTS  Plus  supervisor
nd the  patient  or  his/her  relatives  questions  on
heir regularity  in  adhering  to  treatment.
The  forms  were  checked  for  errors  and  cor-
ected on  the  same  day  of  data  collection.  The  data
ere entered  into  an  Excel  2007  worksheet,  and
ata entry  was  performed  using  strict  check  ﬁles
n Microsoft  Excel.  Data  were  cleaned,  checked  for
iscrepancies  and  rectiﬁed.  Data  analysis  was  per-
ormed with  Epi  Info  7.0.8.0.
perational deﬁnitions
DR  —  TB,  cure,  treatment  completed,  death,
reatment failure,  and  treatment  default  were
eﬁned as  per  RNTCP  guidelines  [11].
Successful  outcome:  Cure  and  completion  of
reatment  were  considered  to  represent  successful
utcome  [11].
Non-successful  outcome: Defaults,  death,
witched to  category  V  treatment,  failure  and
till on  treatment  were  considered  to  represent
on-successful  outcomes  [11].
esults
f  all  enrolled  patients  (146),  information  on  the
utcome was  available  for  145  patients,  as  1  patient
efused  to  provide  consent.  Out  of  145  patients,
n interview  was  performed  for  142  patients,  as  3
atients were  transferred.
In  the  study  population,  102  patients  (71.83%)
ere males  and  40  patients  (28.16%)  were  females,
ith an  overall  mean  age  of  34.83  ±  12.19  years.
hirty-seven (92.5%)  female  patients  were  of  repro-
uctive age  (15—45  years).  In  terms  of  education,
0.71% patients  of  142  were  literate.  However,
9.29% patients  were  illiterate.  The  majority  of  the
atients interviewed  were  Hindus  (134,  94.36%)  and
he rest  were  Muslims.  Most  of  the  patients  (107,
8.02%)  were  married.  At  the  time  of  the  interview,
32, 22.53%)  patients  were  unemployed.
In our  study,  83.44%  patients  were  on  category  II
reatment  before  the  initiation  of  Category  IV  treat-
ent.  Among  145  patients,  87  (60%)  were  resistant
o all  four  drugs  (isoniazid,  rifampicin,  ethamb-
tol and  streptomycin).  Approximately  29  (20%)
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oFigure  1  Treatment  outcome  of  pat
ere  resistant  to  isoniazid,  rifampicin  and  strep-
omycin  and  18  (12.41%)  were  resistant  to  both
soniazid and  Rifampicin.  Two  patients  were  resis-
ant to  rifampicin  and  streptomycin.  Six  (4.13%)
ere resistant  to  isoniazid,  rifampicin  and  ethamb-
tol.  Only  two  patients  were  resistant  to  rifampicin
nd ethambutol  and  one  was  resistant  to  rifampicin
nly.
Fig.  1  shows  the  treatment  outcome  at  the  end
f treatment.  Of  those  145  patients,  48  (33.1%;
I —  24.88—40.68%)  were  cured  and  8  (5.5%;  CI  —
.88—11.46%) completed  treatment.  Therefore,  56
38.6%) patients  were  successfully  treated  as  per
ur working  deﬁnitions,  producing  a  success  rate
f 38.6%.  Forty-three  (29.7%;  CI  —  22.36—37.04%)
atients died  during  treatment,  and  32  (21.1%;  CI
 15.61—29.70%)  patients  defaulted  during  treat-
ent.  Patients  with  treatment  failure  —  those  who
emained  positive  at  the  end  of  treatment  —  consti-
uted 6.2%  (CI  —  2.88—11.46%)  of  the  study  cohort
9/145). Only  one  patient  was  switched  to  cate-
ory V  treatment.  Four  patients  (2.8%)  were  still  on
reatment  30  months  after  starting  treatment.  We
ound that  81  (55.9%)  were  compliant  with  MDR-TB
reatment.
Table  1  shows  the  association  between  the
ifferent socio-demographic  factors  and  previous
reatment  proﬁles  leading  to  successful  or  unsuc-
essful  outcomes  of  patients  on  MDR-TB  treatment
n the  ﬁrst  year  of  initiation  of  DOTS  Plus  in  Baroda.
ut of  146  patients,  2 were  HIV-positive.  Of  these
wo HIV-positive  patients,  one  was  cured  and  one
as defaulter.  Because  there  were  only  two  HIV-
ositive  patients,  HIV  positivity  was  not  included
n the  bivariate  analysis.  Factors  associated  with  a
igniﬁcant difference  in  the  outcomes  were  income
nd education.  After  applying  logistic  regression  to
hese factors,  only  education  was  signiﬁcantly  asso-
iated with  treatment  outcome  (Table  2).
The treatment  success  rate  was  2.4  times  higher
n literate  patients  than  illiterate  patients.  The
p
S
p
e put  on  MDR-TB  treatment  (N  =  145).
reatment  success  rate  was  2.19  times  higher
mong high  and  middle  income  groups  as  compared
o lower  socio-economic  groups,  but  the  difference
as not  found  to  be  statistically  signiﬁcant—it  was
orderline  (CI:  0.991—4.836).
iscussion
he  2010  data  regarding  treatment  outcome  at
4 months,  reasons  for  default  in  MDR  treatment,
nd side  effects  &  compliance  during  treatment
mong MDR-TB  patients  at  the  DOTS  Plus  Site  Bar-
da showed  that  at  the  end  of  treatment,  33.1%
ere cured  and  5.5%  had  completed  treatment.
herefore, 38.62%  had  a successful  treatment  out-
ome, 6.2%  exhibited  treatment  failure,  0.7%  were
ut on  Category  V treatment,  and  2.8%  were  still
n treatment.
Similar  ﬁndings  were  observed  by  Calver  et  al.,
ockman  et  al.  and  Jeon  et  al.,  who  found  suc-
ess rates  of  31.3%  and  37.1%,  respectively  [12—14].
eimane et  al.  in  Latvia  also  similarly  reported  a
ure rate  of  67.6%,  a  treatment  completion  rate  of
.6%, a death  rate  of  5.7%,  default  14.5%,  and  a fail-
re rate  of  10.3%;  0.1%  were  still  on  treatment  [15].
any studies  have  reported  higher  success  rates
s compared  to  our  study.  Other  authors  have  also
eported  high  success  rates  varying  from  55%  to  70%
15—24].  Our  results  are  not  comparable  to  these
tudies  because  of  the  differences  in  the  deﬁnition
f treatment  success,  designs,  and  regions.
Nearly half  of  the  patients  had  discontinued
heir treatment  because  either  they  had  defaulted
21.1%) or  died  (29.7%)  during  the  course  of  treat-
ent. In  South  Africa,  a  study  by  Holtz  et  al.
bserved that  30%  of  patients  defaulted  and  19%
atients  died  before  6 months  of  treatment  [25].
imilar default  and  death  rates  among  MDR  TB
atients  were  also  reported  by  Datta  et  al.,  Calver
t al.  and  Issakidis  et  al.  [12,16,21]. Compared
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Table  1  Bivariate  analysis  of  factors  affecting  treatment  outcome.
Variable  Treatment  outcome  N  (142)  X2 value  P value
Group  Success  Non-success  Total
Age 18—30 24  (48%)  26  (52%)  50 3.741  0.154
30—50 27  (38%) 44  (57.14%) 71
≥50  5  (23.8%)  16  (76.2%)  21
Sex Male  39  (38.20%)  63  (61.8%)  102 0.0767 0.7819
Female  17  (42.5%)  23  (57.5%)  40
Religion Hindu  51  (37.5%)  85  (62.5%)  136 3.3174  0.0686
Other  5  (83.3%)  1  (16.7%)  6
Education Illiterate  15  (26.8%)  41  (73.2%)  56 5.3523  0.0207
Literate  41  (47.7%)  45  (52.3%)  86
Occupation Skilled/Semi-skilled  26  (49.0%)  27  (50.9%)  53
Unskilled  20  (35.1%)  37  (64.9%)  57 3.403 0.1824
Unemployed  10  (31.2%)  22  (68.8%)  32
Income Lower  45  (36.0%)  80  (64.0%)  125 4.0311  0.0447
Middle  and  upper  11  (68.7%)  6  (37.5%)  17
Marital
status
Married  37  (34.6%)  70  (65.4%)  107 3.5027  0.0613
Others  19  (52%)  16  (48%)  35
Residence Urban  7  (53.8%)  6  (46.2%)  13 1.847  0.3972
Rural 44  (39.3%) 68  (60.7%)  112
Urban  slum 5 (29.4%)  12  (70.6%)  17
BMIa ≤18.5  50  (39.4%)  77  (60.6%)  127 0.0539  0.8164
>18.5  6  (40.0%)  9  (60.0%)  15
Addiction Yes 15  (31.3%)  33  (68.8%)  48 1.8592  0.1727
No  42  (44.7%) 52  (55.3%) 94
Drug  resistance ≤2  drugs  8  (36.4%)  14  (63.6%)  22 0.0070  0.9334
>2  drugs  48  (40.0%)  72  (60.0%)  120
Distance  to  DOTS
center  (IP)b
<2  km  40  (38.8%)  63  (61.2%)  103 0.1051 0.7458
2—5  km  17  (43.5%)  22  (56.4%)  39
Distance  to  DOTS
center  (CP)c
<2  km  45  (48.4%)  48  (51.6%)  93 0.2535  0.6145
2—5  km  11  (57.9%)  8  (42.1%)  19
ADRd Yes  30  (38.5%)  48  (61.5%)  78 0.0776  0.7805
No  27  (42.1%)  37  (57.9%)  64
a BMI, body mass index.
b IP, intensive phase.
c CP, continuation phase.
d ADR, adverse drug reactions.
Table  2  Multivariate  analysis  of  factors  affecting
treatment  outcome.
Exp  (B)  95.0%  CI  for  Exp  (B)
Lower  Upper
Education
(illiterate)
2.444  1.170  5.107
Income
Lower  income
2.190  .991  4.836
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so  our  study,  low  default  and  death  rates  were
bserved in  studies  conducted  by  Shin  et  al.,
eimane et  al.,  Kurbatova  et  al.  and  Johnston  et  al.
15,22—24].
In  our  study,  education  and  income  were  found
o be  signiﬁcantly  associated  with  outcome  in
ivariate analysis.  However,  upon  applying  logis-
ic regression  analysis,  it  was  found  that  only
ducation was  signiﬁcantly  associated  with  good
utcome.  Toczek  et  al.  exhibited  similar  ﬁnd-
ngs: literacy  was  independently  associated  with
uccess  rate  [26]. However,  many  studies  and  a
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[nd  of  Treatment  outcome  among  MDRTB  patients  
eta-analysis  on  MDR  TB  showed  an  associ-
tion between  gender,  alcohol  addiction,  low
MI, irregular  treatment  and  smoking  habits
13,22,27—29].
Limitations:  The  long  time  interval  between
efault from  present  treatment  and  the  interview
ould have  resulted  in  a  recall  bias.
onclusions
he  success  rate  was  38%  (33%  cured  and  5%  com-
leted treatment)  among  MDR  TB  patients.  The
ase fatality  rate  (CFR)  was  29.7%,  while  the  treat-
ent failure  rate  was  21%.
In bivariate  analysis,  literacy,  marital  status
nd income  were  found  to  be  signiﬁcantly  associ-
ted with  treatment  success  rate  among  MDR  TB
atients.  When  logistic  regression  was  applied,  only
iteracy was  found  to  be  independently  associated
ith success  rate  among  MDR  TB  patients.
ecommendations
here  is a  need  for  all  patients  with  multidrug-
esistant tuberculosis  to  be  counseled  on  adverse
rug reactions,  treatment  adherence  and  duration
f treatment  before  the  initiation  of  treatment,
hich should  again  be  reinforced  during  treatment.
hese initiatives  may  lead  to  better  compliance  and
inimizing  default  rate.
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